Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Urban Company IPO Review & Investor Guide

By Jagat Joshi
September 15, 2025

Urban Company IPO will be open for Subscription on September 10, 2025, while the closing date is September 12, 2025. The Urban Company IPO price band is set between ₹98 to ₹103 per share, with a face value of ₹1 each. As per the RHP, the company plans to raise around ₹472 crores through an Initial public offering (IPO).

For investors, it can be quite challenging to decide if the Urban Company IPO is a good investment. If you are unsure and still thinking about whether to apply or skip this IPO, don’t worry. In this article, we present the top key factors and a detailed review of the Urban Company IPO. This will help you analyze the strengths, risks, and financial details of the Urban Company, previously known as UrbanClap, improving your investment decision.

About Company

Incorporated in December 2014, Urban Company Limited is one of the prominent tech-based online marketplaces that provide home and beauty services. The company has a presence across 51 cities that include India, the UAE, and Singapore, excluding Saudi Arabia, where it works through a joint venture.

Urban Company allows customers to easily book various services, including cleaning, pest control, electrician, plumbing, carpentry, appliance servicing and repair, on-demand home-help assistance, painting, skincare, hair grooming, and massage therapy. All of these services are offered by trained professionals anytime, anywhere, to meet the customer’s requirements. The company focuses on offering a quality, reliable, and standardized service experience. The company also offers training, tools, financing, insurance, and branding tools to professionals in order to help them improve their quality and income. The company had an average of 54,347 active service professionals each month.

Strengths

Urban Company is one of the reputed companies that focuses on quality, reliability, and is trusted by customers.

The company consists of a strong, dedicated, experienced team of professionals with in-house training, giving them the right tools and materials.

Developed a reputation for inventing innovative products for service professionals in order to enhance the consumer experience.

Urban Company is run by an experienced board and professional management team who have over 10 years of experience.

Weaknesses

Earlier, the company had faced net losses and negative operating cash flow. If the company fails to control the losses or grow its revenue, it can negatively affect the business, cash flow, and overall financial performance.

The company has built a reputation for offering customers a good experience; if it is unable to continue to do so, it can badly impact the business performance and cash flow.

Not being able to attract and keep the service professionals on its platform can negatively affect the business.

The business generated a reputation of being one of the leading companies under the brand name “Urban Company”. Not being able to maintain the reputation can impact the brand growth, reputation, cash flows, and overall performance.

Urban Company IPO Review

Reviewer	Recommendation
Lakshmishree Investment & Securities Ltd	Apply
DRChoksey Finserv Private Limited	Apply
Arihant Capital Markets Ltd	Apply
BP Equities (BP Wealth)	Apply
Canara Bank Securities Ltd	Apply
Capital Market	May Apply
ICICI Direct	Neutral
Mehta Equities	Apply
SMC Global	Neutral
Sushil Finance Ltd	Apply

Urban Company IPO Details

IPO Open Date:	September 10, 2025
IPO Close Date:	September 12, 2025
Face Value:	₹1 Per Equity Share
IPO Price Band:	₹98 to ₹103 Per Share
Issue Size:	Approx ₹1900 Crores
Fresh Issue:	Approx ₹472 Crores
Offer for Sale	Approx 13,86,40,776 Equity Shares
Registrar	MUFG Intime India Pvt. Ltd.
IPO Lead Managers	Kotak Mahindra Capital Co.Ltd. Morgan Stanley India Co.Pvt.Ltd. Goldman Sachs (India) Securities Pvt.Ltd. JM Financial Ltd.
Basis of Allotment	September 15, 2025
IPO Listing Date:	September 17, 2025
Listing	BSE, NSE

Financial Performance Trend Details

Particulars	Fiscal 2025	Fiscal 2024	Fiscal 2023
Revenue from Operations	11,444.65	8,280.18	6,365.97
EBITDA	120.91	(1,190.12)	(2,976.92)
EBITDA Margin (%)	0.37%	(4.64)%	(14.33)%
Net Profit after Tax	239.77	-92.77	-312.48
Return on Net Worth (%)	36.20%	25.65%	24.84%
Reserves and Surplus	2,646.12	2,404.69	2,402.82

Key Indicators

KPI	Values
RoNW	13.35%
Price to Book Value	8.27

Promoters & Track Records, if any

Abhiraj Singh Bhal is the Chairperson, Managing Director, and Chief Executive Officer of the Company, responsible for overall strategy, business growth, market expansion, operations, and investor relations holds 97,762,500 Equity Shares in the company.

Raghav Chandra is the Executive Director and Chief Technology and Product Officer of the Company, responsible for product technology, design, and automation holds 97,762,500 Equity Shares in the company.

Varun Khaitan is the Executive Director and Chief Operating Officer of the company, responsible for business operations across the services and products business in India and overseas holds 97,762,500 Equity Shares in the company.

Expansion

The proceeds raised from the fresh issue will be utilized for the expenditure on new technology development and cloud infrastructure.
Some funds will be used for lease payments for the offices.
Many funds will be utilized towards marketing activities.
Lastly, the remaining funds will be used for the company’s general corporate purposes.

Urban Company IPO – Should You Apply or Not?

According to the Redseer Report, India’s home service industry shows a huge market potential. As the home service industry is still unorganized and offline, the Urban Company offers an excellent opportunity by giving them reliable, high-quality, and standardized services.

The Consumer Excellence, Service professional empowerment, technology-enabled platform, and improved financial performance make this IPO an attractive choice to invest in. As of September 9, 2025, the Urban Company IPO GMP is ₹36, showcasing an excellent listing of around 30 – 35%. A cautious investor must apply for this IPO only after analyzing the company’s financials, cash flow, weaknesses, and strengths first. Investors who have a good risk appetite can apply for this IPO for long-term growth.

Please Note:

This article is written using information from the company’s RHP (Red Herring Prospectus) data and online sources. If you have any queries, kindly contact the IPO Watch Team.

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.